Kim Christina J, Dessureault Sophie, Gabrilovich Dimitry, Reintgen Douglas S, Slingluff Craig L
Department of Surgery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Cancer Control. 2002 Jan-Feb;9(1):22-30. doi: 10.1177/107327480200900104.
Immunotherapy for cancers is based on the principle that the host's immune system is capable of generating immune responses against tumor cells. Currently available treatments for melanoma patients are limited by poor response rates. Interferon-a has been approved for adjuvant treatment of stage III melanoma with improved survival. New and more innovative approaches with improved efficacy are needed.
We reviewed the various new approaches and strategies for immunotherapy for the treatment of melanoma.
Immunotherapy for melanoma includes a number of different strategies with vaccines utilizing whole cell tumors, peptides, cytokine-mediated dendritic cells, DNA and RNA, and antibodies.
A variety of approaches can be used to enhance immune reactivity in patients with melanoma. Preclinical studies and initial clinical trials have shown promising results. Additional clinical trials are currently ongoing to evaluate the clinical efficacy and the associated toxicities of these novel treatment strategies.
癌症免疫疗法基于宿主免疫系统能够产生针对肿瘤细胞的免疫反应这一原理。目前黑色素瘤患者可用的治疗方法受限于低反应率。干扰素-α已被批准用于III期黑色素瘤的辅助治疗，可提高生存率。需要新的、更具创新性且疗效更佳的方法。
我们回顾了用于治疗黑色素瘤的免疫疗法的各种新方法和策略。
黑色素瘤免疫疗法包括多种不同策略，如使用全细胞肿瘤、肽、细胞因子介导的树突状细胞、DNA和RNA以及抗体的疫苗。
可采用多种方法增强黑色素瘤患者的免疫反应性。临床前研究和初步临床试验已显示出有前景的结果。目前正在进行更多临床试验以评估这些新型治疗策略的临床疗效及相关毒性。
